Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 3/20 | 0.33 |
| ▸ | SCN1A | P35498 | 1/20 | 0.32 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.32 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.30 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20068845 | 0.93 | RET (0.35) | RETSCN1ASCN2ASCN3A | |
| SCHEMBL22857016 | 0.89 | RET (0.37) | RET | |
| SCHEMBL20070401 | 0.81 | CYP2D6 (0.34) | RET | |
| SCHEMBL20068840 | 0.79 | SCN1A (0.33) | RETSCN1ASCN2ASCN3AEPHX2 | |
| SCHEMBL20069071 | 0.78 | SCN1A (0.35) | RETSCN1ASCN2ASCN3AEPHX2 | |
| SCHEMBL17749033 | 0.76 | OPRM1 (0.36) | SCN1ASCN2ASCN3AEPHX2OPRD1 | |
| SCHEMBL13103020 | 0.76 | DRD2 (0.40) | SCN1ASCN2ASCN3AEPHX2CYP1A2 | |
| SCHEMBL20147529 | 0.75 | MMP9 (0.35) | RET | |
| SCHEMBL20069498 | 0.75 | MMP9 (0.35) | RET | |
| SCHEMBL22856998 | 0.74 | RET (0.33) | RET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180148445-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180148445-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, BRAF, RAF1 | RET 1/4885SCN1A 1522/4885SCN2A 3348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.